European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact
Guidelines

Muscle-invasive and Metastatic Bladder Cancer

Want to read the guideline in your own time? Download the PDF

Download full guideline

Looking for a quick overview? Check the pocket guidelines.

Download pocket guidelines
Full text guidelineSummary of ChangesPublications & AppendicesPanelRelated content
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
2025
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • No elements found. Consider changing the search query.
  • List is empty.

For the 2025 MIBC Guidelines new and relevant evidence was identified, collated and appraised through a structured assessment of the literature for all sections of the Guidelines. Key changes include:

  • New summary of evidence and recommendation in section 6.5 for use of susceptible FGFR3 alterations to select patients with unresectable or metastatic urothelial carcinoma for treatment with erdafitinib.
  • Significant adaption and update to the recommendations for pre- and post-operative radiotherapy in section 7.2.3.
  • Significant adaption and update to the summary of evidence and recommendation in section 7.3.3.2.1 sexual-preserving techniques in women.
  • New recommendation in section 7.3.10 related radical cystectomy and urinary diversion based on the results of the SWOG trial. In addition, the recommendation related to hospital volume in this section has been adapted.
  • New recommendation in section 7.4.1 for salvage cystectomy after trimodality therapy.
  • New recommendation in section 7.5.4.1. for manage all patients who are candidates for trimodality bladder-preserving treatment in a multidisciplinary team setting using a shared-decision making process.
  • Significant adaption and update to the recommendation for adjuvant nivolumab in selected patients with pT3/4 and/or pN+ disease not eligible for, or who declined, adjuvant cisplatin-based chemotherapy in section 7.6.3. Upgraded strength rating.
  • Updated of the summary of evidence in section 7.7.9 and addition of a new recommendation for metastatic disease in this section regarding antibody drug conjugate Trastuzumab deruxtecan in case of Her2 over expression. In addition the recommendations on Sacituzumab govitecan have been removed as the manufacturer has withdrawn FDA approval for this product.
  • Update of section 8.1 follow-up for MIBC.
  • Update of figures 7.1 and 7.2.
About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer